Skip to main content

Top Menu

  • Contact Us
  • Media Centre
  • Staff
  • About Us
    • About CCTG
    • Committee Leadership
    • CCTG Scientific Leadership
    • CCTG Management
    • Careers at CCTG
    • CCTG policies
    • Contact us
  • Patients & Families
  • Disease Site Listings - Public

    Disease Site Listings - Public

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Multi-Site
    • Sarcoma
    • Symptom Control
  • Disease Site Listings - Members

    Disease Site Listings - Members

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
  • Clinical Trials
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Clinical trials - overview
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Publications

    Mobile CCTG Clinical Trials

    • Member Trial Pages
    • Public Trial Pages
    • Publications

    Protecting Cancer Patients from COVID-19

    In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.

    More >>

    Recently Activated Trials

    CO29

    Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)

    More >>

    HDC1

    Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

    More >>

    MA40

    Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

    More >>

    OV26

    Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

    More >>
  • Member Resources

    Member Links

    • Current Trial pages
    • Become a member
    • Toolbox
    • Funding information
    • Compliance and oversight
    • Audit, inspection & partner compliance
    • Generic protocols
    • Standing committees
    • Disease site & IND committees
    • Terms of reference
    • Group newsletter: CCTG Connection
    • Help & Support

    CCTG Announces Initiation of IND.239

    CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.

    More >>

    Planned Trials

    CXC2

    Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

    HD11

    Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

    I240

    Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

    More >>

    PAC3

    Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

    Disease Site Committees

    • Brain
    • Breast
    • Gastro-Intestinal
    • Gynecologic
    • Genito-Urinary
    • Head & Neck Working Group
    • Hematologic
    • IND
    • IND Executive
    • Lung Disease
    • Melanoma
    • Sarcoma
  • Meetings & Education
  • Search

  • Donate
  • Toolbox
    • Applications
    • >>  EDC (Medidata Rave)
    • >>  iMedidata
    • >>  Mango
    • >>  Ripple
    • >>  Lettuce
    • >>  Sprout (ePRO)
    • Exposure Reporting
    • >>  CTEP website
    • >>  CTCAE v5.0 booklet
    • >>  CTCAE v4.0 booklet
    • >>  CTCAE v3.0 booklet
    • >>  CTEP-AERS reporting
    • >>  EDC SAE (paper report)
    • >>  Pregnancy reporting form
    • >>  Exposure reporting form
    • Support
    • >>  Passwords management
    • >>  CCTG contacts
    • >>  Support information
    • Tissue Bank
    • >>  Tissue Bank
    • >>  Inventory
    • >>  Tissue research
    • Reports
    • >>  Accrual utility (Monthly site accrual)
    • >>  Safety reports
    • >>  Papaya
    • >>  Ethics
    • >>  Trial closure
    • Data Management
    • >>  Baseline symptoms & adverse events
    • >>  Concomitant medications template
    • >>  SI conversion table
    • >>  iRECIST & RECIST guidelines
    • Training
    • >>  NIH ethics training
    • >>  Division 5 part C
    • >>  Good clinical practice
    • >>  Site training
    • >>  Supplementary training
  • Contact Us
  • Media Centre
  • Staff

  For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

CCTG Scientific Leadership

Researchers and Faculty

CCTG Scientific Leadership

Janet Dancey

Janet Dancey
Director

Lesley Seymour

Lesley Seymour
Director, IND

CCTG Senior Investigators

Annette Hay

Annette Hay
Senior Investigator

Chris O'Callaghan

Chris O'Callaghan
Senior Investigator

Wendy R. Parulekar

Wendy R. Parulekar
Senior Investigator

Lois Shepherd

Lois Shepherd
Senior Investigator

Harriet Richardson

Harriet Richardson
Senior Investigator

James Taylor

James Taylor
Senior Investigator

Joseph Pater

Joseph Pater
Senior Investigator

Pierre-Olivier Gaudreau

Pierre-Olivier Gaudreau
Senior Investigator, IND

Tricia Cottrell

Tricia Cottrell
Senior Investigator

Isabelle Gauthier

Isabelle Gauthier
Senior Scientist, Business Development & Collaborations

 

CCTG Senior Biostatisticians

Bingshu Chen

Bingshu Chen
Senior Biostatistician

Dongsheng Tu

Dongsheng Tu
Senior Biostatistician

Keyue Ding

Keyue Ding
Senior Biostatistician

Wei Tu

Wei Tu
Senior Biostatistician

Landing Page - About Us

  • About CCTG
  • Committee Leadership
  • CCTG Scientific Leadership
  • CCTG Management
  • Careers at CCTG
  • CCTG policies
  • Contact us
  • Partnerships 500+ trials in 40+ countries
  • IND Program 36+ years experience in 205+ drug trials
  • Tissue Bank 300,000+ samples from 120+ trials
  • Network 2100+ investigators at 85+ sites
  • Become a CCTG Investigator

Footer Menu

  • About us
  • Patients & Families
  • Clinical trials
  • Member resources
  • Meetings & Education
  • Publications
  • Toolbox
  • Contact us
  • Media centre
  • Staff
  • Terms & cookies

CANADIAN CANCER TRIALS GROUP

Cancer Research Institute
Queen's University

10 Stuart Street
Kingston, Ontario
Canada K7L 3N6

A NATIONAL PROGRAM OF THE:

 

OPERATIONS AND STATISTICAL CENTRE LOCATED AT:

PROUDLY AFFILIATED WITH:

© Canadian Cancer Trials Group, 2021 | Terms & Conditions Facebook LinkedIn TwitterYouTube